Dr. Reddy's Loses Zyprexa Patent Fight In UK Court

By Erin Fuchs

Law360, New York (December 18, 2009, 4:48 PM ET) -- A U.K. appeals court has upheld the validity of Eli Lilly & Co.'s patent for Zyprexa, rejecting Dr. Reddy's Laboratories Ltd.'s contention that an earlier Lilly patent rendered the patent for the blockbuster schizophrenia drug invalid.

The High Court of Justice, Court of Appeal, sided with Lilly on Friday, shooting down the Dr. Reddy's challenge and affirming a decision by the High Court of Justice, Chancery Division.

The generic-drug maker had argued that a disclosure for a prior Lilly patent for a broad class of compounds...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles